A citation-based method for searching scientific literature

Sunzeyu Huang, Nathaniel J Stillson, Jonathan E Sandoval, Chitoh Yung, Norbert O Reich. Bioorg Med Chem Lett 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Jehad Almasri, Hassan B Alkhateeb, Belal Firwana, Mohamad Bassam Sonbol, Moussab Damlaj, Zhen Wang, M Hassan Murad, Aref Al-Kali. Syst Rev 2018
8
100


High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
L Campos, J P Rouault, O Sabido, P Oriol, N Roubi, C Vasselon, E Archimbaud, J P Magaud, D Guyotat. Blood 1993
616
100

How proteolysis drives the cell cycle.
R W King, R J Deshaies, J M Peters, M W Kirschner. Science 1996
100

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
Kira Allmeroth, Moritz Horn, Virginia Kroef, Stephan Miethe, Roman-Ulrich Müller, Martin S Denzel. Leukemia 2021
8
100

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response.
Eva De Smedt, Hui Lui, Ken Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne. Front Oncol 2018
20
100

Azacitidine: a novel agent for myelodysplastic syndromes.
Meaghan Sullivan, Kristine Hahn, Jill M Kolesar. Am J Health Syst Pharm 2005
12
100

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
835
100

DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Daelynn R Buelow, Jason T Anderson, Stanley B Pounds, Lei Shi, Jatinder K Lamba, Shuiying Hu, Alice A Gibson, Emily A Goodwin, Alex Sparreboom, Sharyn D Baker. Clin Transl Sci 2021
2
100

Mechanisms of resistance to azacitidine in human leukemia cell lines.
Piyanuch Sripayap, Tadashi Nagai, Mitsuyo Uesawa, Hiroyuki Kobayashi, Tomonori Tsukahara, Ken Ohmine, Kazuo Muroi, Keiya Ozawa. Exp Hematol 2014
23
100


DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.
Maria E Figueroa, Sanne Lugthart, Yushan Li, Claudia Erpelinck-Verschueren, Xutao Deng, Paul J Christos, Elizabeth Schifano, James Booth, Wim van Putten, Lucy Skrabanek,[...]. Cancer Cell 2010
571
100

Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.
B Quesnel, G Guillerm, R Vereecque, E Wattel, C Preudhomme, F Bauters, M Vanrumbeke, P Fenaux. Blood 1998
266
100

Targeting DNA methylation.
Jean-Pierre J Issa, Hagop M Kantarjian. Clin Cancer Res 2009
294
100

Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.
Ainsley Mike Antao, Apoorvi Tyagi, Kye-Seong Kim, Suresh Ramakrishna. Cancers (Basel) 2020
23
100

Targeting Polo-like kinase in cancer therapy.
Yan Degenhardt, Thomas Lampkin. Clin Cancer Res 2010
184
100

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
May Daher, Juliana Elisa Hidalgo Lopez, Jasleen K Randhawa, Kausar Jabeen Jabbar, Yue Wei, Naveen Pemmaraju, Gautam Borthakur, Tapan Kadia, Marina Konopleva, Hagop M Kantarjian,[...]. Am J Hematol 2017
16
100



A pilot pharmacokinetic study of oral azacitidine.
G Garcia-Manero, M L Stoltz, M R Ward, H Kantarjian, S Sharma. Leukemia 2008
49
100

Induction of tumors in mice by genomic hypomethylation.
François Gaudet, J Graeme Hodgson, Amir Eden, Laurie Jackson-Grusby, Jessica Dausman, Joe W Gray, Heinrich Leonhardt, Rudolf Jaenisch. Science 2003
100

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
Shuchi Agrawal, Wolf-Karsten Hofmann, Nicola Tidow, Mathias Ehrich, Dirk van den Boom, Steffen Koschmieder, Wolfgang E Berdel, Hubert Serve, Carsten Müller-Tidow. Blood 2007
95
100

Auer bodies in acute myeloid leukaemia patients.
H T Hassan, J K Rees. Pathol Res Pract 1990
4
100

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.
Guido Cavaletti, Alessandra Gilardini, Annalisa Canta, Laura Rigamonti, Virginia Rodriguez-Menendez, Cecilia Ceresa, Paola Marmiroli, Mario Bossi, Norberto Oggioni, Maurizio D'Incalci,[...]. Exp Neurol 2007
191
100

Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation.
Maria Rius, Carlo Stresemann, Daniela Keller, Manuela Brom, Esther Schirrmacher, Dietrich Keppler, Frank Lyko. Mol Cancer Ther 2009
43
100

Microbiological production of 5-azacytidine. I. Production and biological activity.
L J Hanka, J S Evans, D J Mason, A Dietz. Antimicrob Agents Chemother (Bethesda) 1966
17
100


Erasers of histone acetylation: the histone deacetylase enzymes.
Edward Seto, Minoru Yoshida. Cold Spring Harb Perspect Biol 2014
711
100

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
D Chen, M Frezza, S Schmitt, J Kanwar, Q P Dou. Curr Cancer Drug Targets 2011
473
100

Programming of Cell Resistance to Genotoxic and Oxidative Stress.
Ilya O Velegzhaninov, Vitaly A Ievlev, Yana I Pylina, Dmitry M Shadrin, Olesya M Vakhrusheva. Biomedicines 2018
6
100

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
James J Driscoll, Dheeraj Pelluru, Konstantinos Lefkimmiatis, Mariateresa Fulciniti, Rao H Prabhala, Philip R Greipp, Bart Barlogie, Yu-Tzu Tai, Kenneth C Anderson, John D Shaughnessy,[...]. Blood 2010
85
100

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
T Hideshima, P Richardson, D Chauhan, V J Palombella, P J Elliott, J Adams, K C Anderson. Cancer Res 2001
100

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.
Depei Wu, Xin Du, Jie Jin, Zhijian Xiao, Zhixiang Shen, Zonghong Shao, Xiao Li, Xiaojun Huang, Ting Liu, Li Yu,[...]. Adv Ther 2015
16
100

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
Esther A Zaal, Wei Wu, Gerrit Jansen, Sonja Zweegman, Jacqueline Cloos, Celia R Berkers. Cancer Metab 2017
62
100

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Teru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, Masaharu Akiyama, Nicholas Mitsiades, Constantine Mitsiades, Klaus Podar, Nikhil C Munshi, Paul G Richardson, Kenneth C Anderson. Oncogene 2003
135
100

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Edvardas Kaminskas, Ann Farrell, Sophia Abraham, Amy Baird, Li-Shan Hsieh, Shwu-Luan Lee, John K Leighton, Hasmukh Patel, Atiqur Rahman, Rajeshwara Sridhara,[...]. Clin Cancer Res 2005
269
100

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux,[...]. N Engl J Med 2020
341
100

Revised international prognostic scoring system for myelodysplastic syndromes.
Peter L Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo Garcia-Manero, Francesc Solé, John M Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus,[...]. Blood 2012
100

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Hagop M Kantarjian, Gail J Roboz, Patricia L Kropf, Karen W L Yee, Casey L O'Connell, Raoul Tibes, Katherine J Walsh, Nikolai A Podoltsev, Elizabeth A Griffiths, Elias Jabbour,[...]. Lancet Oncol 2017
91
100

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Silpa Narayanan, Chao-Yun Cai, Yehuda G Assaraf, Hui-Qin Guo, Qingbin Cui, Liuya Wei, Juan-Juan Huang, Charles R Ashby, Zhe-Sheng Chen. Drug Resist Updat 2020
53
100

Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
H Cechova, P Lassuthova, L Novakova, M Belickova, R Stemberkova, J Jencik, M Stankova, P Hrabakova, K Pegova, H Zizkova,[...]. Neoplasma 2012
25
100

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Rafael Bejar, Allegra Lord, Kristen Stevenson, Michal Bar-Natan, Albert Pérez-Ladaga, Jacques Zaneveld, Hui Wang, Bennett Caughey, Petar Stojanov, Gad Getz,[...]. Blood 2014
390
100

Peroxisome biogenesis disorders.
Catherine Argyriou, Maria Daniela D'Agostino, Nancy Braverman. Transl Sci Rare Dis 2016
27
100

Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy.
Danielle R Bond, Heather J Lee, Anoop K Enjeti. Cancers (Basel) 2020
2
100

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
John S Welch, Allegra A Petti, Christopher A Miller, Catrina C Fronick, Michelle O'Laughlin, Robert S Fulton, Richard K Wilson, Jack D Baty, Eric J Duncavage, Bevan Tandon,[...]. N Engl J Med 2016
440
100

Why methylation is not a marker predictive of response to hypomethylating agents.
Maria Teresa Voso, Valeria Santini, Emiliano Fabiani, Luana Fianchi, Marianna Criscuolo, Giulia Falconi, Francesco Guidi, Stefan Hohaus, Giuseppe Leone. Haematologica 2014
40
100

92
100

DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.
Agnieszka Gnyszka, Zenon Jastrzebski, Sylwia Flis. Anticancer Res 2013
165
100

CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.
K Raj, A John, A Ho, C Chronis, S Khan, J Samuel, S Pomplun, N S B Thomas, G J Mufti. Leukemia 2007
125
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.